Caring for the AKI Survivor: What is Required?
|
|
- Briana Gray
- 5 years ago
- Views:
Transcription
1 Caring for the AKI Survivor: What is Required? Ron Wald, MDCM MPH FRCPC Division of Nephrology St. Michael s Hospital and University of Toronto February 28, 2019
2 A patient in your ICU 65M with DM, HTN, COPD admitted for septic shock in context of urosepsis ventilation and pressors required oliguric, scr 5.1 mg/dl (baseline scr 1.0 mg/dl) CRRT is started
3 Course in hospital After 5 days on CRRT, urine output shows progressive improvement CRRT withdrawn scr stabilizes at mg/dl with no requirement for dialysis x 5 days patient ready for discharge to the ward 10 days later, discharged to Rehab, serum creatinine 1.6 mg/dl
4 Questions for consideration What is the likelihood that this patient will return to his pre-morbid level of kidney function? When should kidney function be rechecked? What are the risks that this patient faces in the coming weeks and months?
5 Objectives To review kidney and non-kidney outcomes of relevance to AKI survivors To review interventions designed to improve outcomes for AKI survivors To discuss recent research on the prediction of adverse kidney outcomes among AKI survivors
6 Threats affecting AKI survivors CKD- de novo/progressive Recurrent AKI Rehospitalization Cardiovascular health Medication errors Quality of life
7 Reversible AKI and the risk of CKD Cohort study in a large health provider in Pennsylvania, Identified 1,997 patients admitted to hospital with AKI (50% increase in scr) who also: Had no evidence of egfr < 60 or urinary abnormalities in preceding year Survived to 90 days following discharge Recovered > 90% of baseline GFR Bucaloiu KI 2012
8 AKI and de novo CKD AKI (n=1610) No AKI (n=3652) Age 63.0 (52.0, 74.0) 63.0 (51.0, 73.0) ICU, % Baseline egfr 97.2 (86.4,110.0) DM HTN CAD (86.1, 109.7) Bucaloiu KI 2012
9 Time to CKD by AKI Status RR for CKD 2.14 (95% CI, ) Bucaloiu KI 2012
10 The risk of chronic dialysis in survivors of AKI-D in Canada Risk of chronic dialysis Adjusted HR: 3.22 ( ) (n=3769) (n=13,598)
11 Recurrent AKI in the US VA Median time to recurrent AKI 64 d ~60% of events occurred within 90 d Key risk factors: Older age Comorbidities (CKD, DM, CAD, dementia) Index hospitalization dx (HF, malignancy, volume depletion) Receipt of chemotherapy Siew et al, JASN 2015
12 AKI survivors are at higher risk of 30-day all-cause rehospitalization ahr=1.53 ( ) Silver et al Am J Med 2016
13 Are there non kidney-related outcomes that we need to worry about?
14 AKI and the risk of major adverse cardiovascular events AKI MI MI + AKI Chawla et al CJASN 2014
15 The risk of heart failure following AKI 1.2M admissions to VA hospitals 150,000 with AKI (mostly stage 1) Matched 1:1 with hospitalized patients who did not experience AKI No patient had pre-existing heart failure Primary outcome: incident heart failure defined as hospitalization with HF or 2 ambulatory visits for HF, within 2 years of index hospitalization Bansal et al AJKD 2018
16 The risk of heart failure following AKI HR 1.23 (95% CI )
17 Cardiovascular health following AKI AKI is a risk factor for de novo hypertension 43,611 normotensive patients hospitalized between An episode of AKI was independently associated with a diagnosis of hypertension (aor 1.22, 95% CI ) with risk higher in greater AKI severity Hsu JASN 2015
18 Quality of life following AKI-D troubling data from the ATN trial 415 participants who survived to Day 60 Health utility measured in 8 domains* on scale of 0 (~ death) to 1 (perfect health) 27% had health utility index of 0 (ie, equal to or worse than death) *vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain Johansen et al, CJASN 2010
19 To summarize AKI is associated with a myriad of bad outcomes including CKD Recurrent AKI and rehospitalization CVD Heart failure Poor HRQoL Are these relationships causal? Does causality matter?
20 Objectives To review kidney and non-kidney outcomes of relevance to AKI survivors To review interventions that may improve outcomes for AKI survivors To discuss recent research on the prediction of adverse kidney outcomes among AKI survivors
21 RAAS blockade after AKI Brar et al JAMA Int Med 2018
22 RAAS blockade after AKI Central research question: Does the prescription of an ACEi or ARB within 6 months after discharge improve survival in AKI survivors? 46,253 Albertans hospitalized with AKI between July 1, March 31, 2013 who survived to discharge 9456 ACEi/ARB recipients matched 1:1 to those who did not receive a ACEi/ARB rx
23 RAAS blockade after AKI
24 Given the complexity of AKI survivors, can enhanced processes of care improve patients outcomes?
25 How can we address these simultaneous threats to AKI survivors? One possible solution: nephrologist-led structured follow-up addresses the inadequate follow-up accorded to AKI survivors recognizes the unique complexity and dynamic nature of this population rooted in data from HF, CAD and COPD populations
26 Nephrology Follow-Up for AKI-D Survivors HR 0.76 (95% CI: ) Seeing a nephrologist within 90 days of discharge associated with a 25% reduction in mortality Harel et al Kidney Int 2013
27 The SMH AKI Follow-Up Clinic initiated at St. Michael s Hospital, Toronto in September 2013 goal was to fill a perceived gap in the care provided to AKI survivors
28 Overview of the SMH AKI Follow-up Clinic Slide courtesy of S. Silver
29 What do we do in the AKI Follow-Up Clinic? BP and albuminuria control cardiovascular prevention as appropriate medication reconciliation sick day medication counselling facilitation of referrals patient and primary care MD education
30 Does any of this work? Nephrologist Follow-up versus USual care after an acute kidney Injury hospitalization (FUSION): A randomized controlled trial Clinicaltrials.gov NCT site RCT, envisioned as a vanguard phase for a definitive clinical trial
31 Research Question Does follow-up with a nephrologist in an AKI Follow-up Clinic within 30-days after a hospitalization complicated by AKI reduce the number of major adverse kidney events at one year compared to patients who do not receive follow-up in an AKI Follow-up Clinic?
32 Eligibility Criteria Inclusion Criteria Age 18 years Kidney Disease Improving Global Outcomes stage 2 AKI and above (including need for dialysis) Exclusion Criteria Kidney transplant recipients Outpatient baseline egfr under 30mL/min/1.73m 2 Patients with a persistent requirement for dialysis Clinical diagnosis or suspicion of: glomerulonephritis, vasculitis, HUS, PCKD, myeloma cast nephropathy Pregnancy Residence at a nursing home facility Palliation as primary goal of care Previously established and ongoing nephrology follow-up
33 Intervention Group Nephrologist visit within 30-days of hospital discharge with further appointments at the discretion of the nephrologist Standardized assessment forms provided to help direct care Routine bloodwork at least every 3 months for 12 months AKI Follow-up Clinic discharge at one year post-randomization
34 Usual Care Group Patient letter outlining AKI diagnosis and followup recommendations Telephone calls by study staff at 3, 6, and 9 months post-randomization Optional nephrology visit at 12 months to act as end-of-study visit participants may still be referred to a nephrologist by their healthcare provider, but they will be triaged as any other nephrology referral
35 Primary Outcome: Major Adverse Kidney Events (MAKE) at 1 Year Composite outcome: Death Chronic dialysis CKD progression Incident CKD = first time egfr is under 60mL/min/1.73m 2 and stays below this value for 3 months Progressive CKD = 25% egfr decrease from known baseline that is <60mL/min/1.73m 2 and the egfr stays below this value for 3 months
36 FUSION Pilot Results: Feasibility 269 eligible patients approached to participate 71 recruited Possible factors highlighting poor participation rates: limited appreciation of AKI in context of a complex stay in hospital too many MD appointments distance from SMH
37 FUSION: Baseline characteristics AKI Clinic (n=34) Age 64 (10) 66 (11) Female Sex 29% 32% ICU 44% 49% Usual Care (n=37) LOS 12 (7-21) days 16 (10-22) days Stage 2 32% 46% Stage 3 68% 54% Baseline egfr 79 (23) 73 (22) Discharge egfr 55 (23) 59 (27) Silver SA et al, unpublished data
38 Alternative approaches to ensure better post-aki care Reduce dependence on return hospital visits Telehealth, home BP checks, PoC monitoring Engage nurse navigators to carry out a multidisciplinary intervention Target the intervention to patients at the highest risk
39 Objectives To review kidney and non-kidney outcomes of relevance to AKI survivors To review interventions that may improve outcomes for AKI survivors To discuss recent research on the prediction of adverse kidney outcomes among AKI survivors
40 Are there some patients who are destined for a higher likelihood of kidney non-recovery? James et al JAMA 2017
41 Prediction of advanced Patient population: CKD after AKI hospitalized with AKI between pre-existing egfr > 45 ml/min/1.73 m 2 survived for > 30 days following discharge 9973 patients in Alberta and 2761 in Ontario Outcome: egfr < 30 ml/min/1.73 m 2 or need for maintenance dialysis between 30 days and 1 year after hospital discharge James et al JAMA 2017
42 Prediction of advanced CKD after AKI
43 This area is receiving increasing attention
44 Care of the AKI survivor: Final points the AKI survivor is a vulnerable patient who remains susceptible to numerous risks well after acute illness has resolved post-discharge follow-up represents an opportunity to close an important healthcare gap patient selection and the nature of the interventions/follow-up are controversial new tools may help focus post-aki care to those most likely to derive benefit
45 Acknowledgements Funding: AFP Innovation Program (SMH and Sunnybrook) Sam Silver Ziv Harel Neill Adhikari, Ali Zahirieh Adic Perez-Sanchez Abhi Kitchlu, Dan Blum ICES Kidney Dialysis Transplantation Program
46 Caring for the AKI Survivor: What is Required? Ron Wald, MDCM MPH FRCPC Division of Nephrology St. Michael s Hospital and University of Toronto February 28, 2019
Chapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationThe role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital
The role of the Nephrologist in Acute Kidney Injury Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital Overview Impact of AKI Need for change Who needs a Nephrologist Are we making
More informationUne promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes
Une promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes Fernando Liaño Hospital Universitario Ramón y Cajal Madrid, España Genéve, 14-12-2012 Une promenade dans l'épidémiologie
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationCKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral
CKD IN THE CLINIC Family Physician Refresher Course Lisa M. Antes, MD April 19, 2017 No disclosures Session Content 1. 2. Recommendations for commonly used medications in CKD Basic principles /patient
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAdding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London
Acute Kidney Injury Adding Insult to Injury Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Content 1. Brief review of AKI and its impact 2. Comments on the
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationNephrology referral - Does my patient need it? Disclosure
Nephrology referral - Does my patient need it? Sophia Chou, MD MSc March 10, 2018 Faculty: Sophia Chou Disclosure Relationships with commercial interest: None Potential conflict of interest: None 1 Objectives
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationDoncaster & Bassetlaw. AKI guidelines for primary care
Doncaster & Bassetlaw AKI guidelines for primary care Contents: FLOW DIAGRAM: MANAGEMENT OF PATIENTS WITH AKI DETECTED IN PRIMARY CARE... 2 FLOW DIAGRAM: MANAGEMENT OF HYPERKALAEMIA.... 3 FLOW DIAGRAM:
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationDisclosures. CKD/ESRD care among vulnerable populations. Objectives. Case: Ms. S 3/12/2016. Delphine Tuot, MDCM, MAS Assistant Professor of Medicine
Disclosures CKD/ESRD care among vulnerable populations I have nothing to disclose Delphine Tuot, MDCM, MAS Assistant Professor of Medicine Objectives Recognize disparities related to kidney health Learn
More informationThe Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD
The Link Between Acute and Chronic Kidney Disease John Arthur, MD, PhD Conventional Dogma Conventional dogma was that if a patient survived and recovered from AKI, he was unlikely to have long-term sequela.
More informationConcept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
More informationAcute Kidney Injury Care in the Chronic Unit
Acute Kidney Injury Care in the Chronic Unit BONNIE B GREENSPAN WITH ASSIST FROM: DENISE MURCEK, JINA BOGLE, MARY SCHIRA, OCTOBER 5, 2017 Objectives At the completion of the session, engaged participants
More informationH2H Early Follow-up Challenge: See You in 7. Webinar #1 Thursday, March 3, :00 pm 4:00 pm ET. Welcome
H2H Early Follow-up Challenge: See You in 7 Webinar #1 Thursday, March 3, 2011 3:00 pm 4:00 pm ET 1 Welcome Take Home Messages Renew your H2H commitment Participate in the first H2H Challenge Help build
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationLas dos caras de la cretinina sérica The two sides of serum creatinine
Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationQBPC Claims Based Provider Quick Reference Guide
QBPC Claims Based Provider Quick Reference Guide Category: Diabetes Chronic Suite ICD-10-CM diagnosis HbA1c Test Codes LOINC Evidence of Treatment for Nephropathy Codes E10; E11; E13 83036-37 17856-6,
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationAcute kidney injury definition, causes and pathophysiology. Financial Disclosure. Some History Trivia. Key Points. What is AKI
Acute kidney injury definition, causes and pathophysiology Financial Disclosure Current support: Center for Sepsis and Critical Illness Award P50 GM-111152 from the National Institute of General Medical
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPositive Impact of Recent Metrics
Seeing Faces on Readmissions and Unmet Metrics Who is getting readmitted after heart failure hospitalizations? Who with HFrEF is discharged without guideline-based medications? Positive Impact of Recent
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDepartment of Nephrology
OUTCOMES DIVISION OF MEDICINE Department of Nephrology About Cleveland Clinic Florida Cleveland Clinic Florida s medical staff are dedicated physicians who have joined the clinic as salaried doctors to
More informationACUTE KIDNEY INJURY. Stuart Linas U. Colorado SOM
ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of dialysis-requiring AKI in last decade JASN 24 37 2013 Question 1 Of patients who recover from an episode of AKI, what percentage
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationSupplementary Online Content
Supplementary Online Content James MT, Neesh P, Hemmelgarn BR, et al. Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. JAMA. doi:10.1001/jama.2017.16326
More informationSouthern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care
Southern Derbyshire Shared Care Pathology Guidelines AKI guidelines for primary care Contents: Flow Diagram: Recommended response time to AKI warning stage test results for adults in primary care 2 Table
More informationUpdate in. Acute Kidney Injury. Mark Devonald Consultant Nephrologist. Nottingham AKI Research Group
Update in Acute Kidney Injury Mark Devonald Consultant Nephrologist If you stay awake you might hear about Why AKI is important Some cases to illustrate some specific points A couple of updates on AKI
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationIdentifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationNephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI)
Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist,
More informationNephrology. 3 rd Year Revision Session 06/05/17 Cathal Hannan
Nephrology 3 rd Year Revision Session 06/05/17 Cathal Hannan Aims Acute Kidney Injury-recognition and management Sample OSCE Station Clinically relevant renal physiology Aetiology of Chronic Kidney Disease
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationGeriatric Nephrology. Murtener Tage
Geriatric Nephrology Murtener Tage 2014 Isabelle.Binet@kssg.ch www.nierenstiftung.ch Plan Geriatric nephrology The elderly with CKD The elderly on dialysis The elderly in transplantation Plan Geriatric
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationLiverpool experience of Community AKI care
Liverpool experience of Community AKI care Shahed Ahmed Consultant Nephrologist and Honorary Lecturer Royal Liverpool University Hospital shahed.ahmed@rlbuht.nhs.uk Is AKI really a problem? 100000, deaths
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationQuality of Care in Early Stage Chronic Kidney Disease
Quality of Care in Early Stage Chronic Kidney Disease 2012 2013 Supplementary Report to the 2015 Alberta Annual Kidney Care Report Kidney Health Strategic Clinical Network December 22, 2015 For more information
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationOutcomes of dialysis in the elderly. DNT March 2011 Dr Céline Foote
Outcomes of dialysis in the elderly DNT March 2011 Dr Céline Foote Increasing number of elderly patients on renal replacement therapy 500 500 Patients per million 400 300 200 100 400 300 200 100 TOTAL
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationWhat should you do next? Presenter Disclosure Information. Learning Objectives. Case: George
2:45 3:45pm Optimizing the Management of Patients with Chronic Kidney Disease SPEAKER Jay B. Wish, MD, FACP Presenter Disclosure Information The following relationships exist related to this presentation:
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationPrimary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationHIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD
HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationAlberta Kidney Care Report February Prevalence and Quality of Care in Chronic Kidney Disease
February 2019 Prevalence and Quality of Care in Chronic Kidney Disease [Type here] Authors This report has been prepared by: Dr. Marni Armstrong, PhD; Assistant Scientific Director of the Kidney Health
More informationChronic renal disease in the elderly: are all pigs to be considered equal?
Chronic renal disease in the elderly: are all pigs to be considered equal? W. Van Biesen, Ghent University Hospital Elwood et al, cjasn, 2013 Elderly and CKD: a thematic synthesis Overview CKD in the
More informationChronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree
Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree Topics CKD background egfr background Patient with egfr Referral Guidelines
More informationThe Health Problem: Guidelines: NHS Priority:
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation research project.
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationTargeting depression after ARDS. Neill Adhikari Sunnybrook Health Sciences and University of Toronto 29 October 2012
Targeting depression after ARDS Neill Adhikari Sunnybrook Health Sciences and University of Toronto 29 October 2012 None Conflicts of interest Objectives Review epidemiology of depression after ARDS Review
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationComparing RRT Modalities: Does It Matter What You Use If The Job Is Done?
Comparing RRT Modalities: Does It Matter What You Use If The Job Is Done? Sean M Bagshaw, MD, MSc Division of Critical Care Medicine University of Alberta Disclosure Consulting: Alere, Baxter, Gambro,
More informationAcute Kidney Injury (AKI) In Primary Care Supporting early detection and consistent management
Acute Kidney Injury (AKI) In Primary Care Supporting early detection and consistent management Responding to AKI Warning Stage Test Results for Adults in Primary Care: Best Practice Guidance AKI in Primary
More informationSo why have CKD stages I and II at all?!
So why have CKD stages I and II at all?! Structural / genetic abnormalities e.g. APKD Significant proteinuria Nephrotic range Microscopic haematoproteinuria in the absence of infection e.g. vasculitis?!!
More informationDonation from Old Living Donors How safe is it? Safe for recipient or donor?
Donation from Old Living Donors How safe is it? Safe for recipient or donor? Pr Lionel Rostaing Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation CHU Grenoble Alpes France lrostaing@chu-grenoble.fr
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationSession 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives
Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives 1. Understand the impact of chronic kidney disease (CKD) as a common condition of the adult US population.
More informationMedicare STRIDE SM Physician Quality Program 2019 Program Overview
Medicare STRIDE SM Quality Program 2019 Program Overview Health Services- Managed by Network Medical Management 2019 Program 1 Medicare Advantage Quality Program Program Overview The Plan will support
More informationOnline clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary
Online clinical pathway for chronic kidney disease (CKD) in primary care February 27, 2015 Dr. Kerry McBrien University of Calgary FACULTY/PRESENTER DISCLOSURE Faculty: Kerry McBrien Relationships with
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationSUPPLEMENTARY INFORMATION
Supplementary information S1 Studies of the effect of AKI duration on outcomes Study Study group (n) Criteria for AKI Definition of RR Outcomes Uchino et al. All patients admitted to (2010) 1 a university-affiliated
More informationCKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry. UK Renal Registry 2013 Annual Audit Meeting
CKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry UK Renal Registry 2013 Annual Audit Meeting Scope of the talk Background CK MAPPS EQUAL My Research Future
More information